Overcoming Volume Limits: The Science of Expanding Cord Blood Cells

Cord blood contains life-saving stem cells, but its limited volume often falls short for adult treatments. Scientists are solving this by expanding stem cells outside the body, increasing their numbers for transplants and therapies. This process, called ex vivo expansion, uses advanced techniques like cytokine cocktails, small molecules (e.g., SR-1, UM171), and co-culture systems to grow cells while keeping them undifferentiated.

Key advancements include the FDA-approved Omisirge (2023), which boosts stem cell counts by 130-fold, cutting recovery times and improving outcomes. This technology now enables a single cord blood unit to meet the needs of larger patients or multiple treatments, making cord blood banking more effective for families. Americord leads in this space with advanced processing and storage methods, ensuring higher cell counts and flexibility for future therapies.

Ex Vivo Expansion: How Scientists Grow Cells Outside the Body

The Ex Vivo Expansion Process

Ex vivo expansion involves growing hematopoietic stem cells outside the body to increase their numbers for transplantation. By mimicking the natural bone marrow environment, researchers can promote cell division while keeping the cells in their undifferentiated state.

The process begins with isolating undifferentiated cells, typically CD34+ or CD133+, using labeled antibodies. These cells are then cultured in a specialized growth medium enriched with recombinant cytokines and growth factors like SCF, TPO, and Flt-3 ligand to encourage proliferation.

To further enhance expansion, modern methods incorporate small molecules such as Nicotinamide, SR-1, and UM171 alongside cytokines. A notable breakthrough came in April 2023 when the U.S. FDA approved Omisirge (Omidubicel-onlv) by Gamida Cell Ltd., the first expanded cord blood product. In a Phase III trial with 125 participants, the nicotinamide-based process increased CD34+ cells by approximately 130-fold over 21 days. This resulted in a median cell count of 9.0 × 10⁶ cells/kg, compared to just 0.3 × 10⁶ cells/kg with traditional cord blood transplants.

The laboratory environment plays a crucial role in this process. Oxygen levels are carefully maintained between 3% and 5%, much lower than the atmospheric 20%, to help preserve the cells' primitive state. Some techniques utilize continuous perfusion bioreactors to supply fresh nutrients and remove waste, while others employ co-culture systems with Mesenchymal Stromal Cells (MSCs) as a supportive layer that replicates the structure of the bone marrow.

These advancements in ex vivo expansion directly lead to better clinical outcomes.

Benefits of Increasing Cell Counts

Refined ex vivo techniques that boost cell counts have significantly improved clinical results. For example, in the Omidubicel trial, patients receiving expanded cells achieved neutrophil engraftment in a median of 12 days, compared to 22 days with standard cord blood transplants. This faster recovery period reduces the risk of severe infections, as shown by a decrease in bacterial or invasive fungal infections from 57% with conventional transplants to 37% with expanded cells.

This technology also addresses the challenge of cord blood's limited volume. Expanded cord blood units now enable treatments for adult patients using a single unit, eliminating the need for two units or alternative donors. Previously, only about 5% of banked cord blood units had enough cells for an average 154 lb (70 kg) adult. With current expansion protocols, nearly 50% of available units now meet this therapeutic threshold.

Current Techniques for Expanding Cord Blood Cells

Using Cytokines to Stimulate Cell Growth

Cytokines are vital signaling molecules that encourage stem cell division. The most effective strategy involves combining three key cytokines: Stem Cell Factor (SCF), Fms-like tyrosine kinase 3 ligand (Flt-3L), and Thrombopoietin (TPO). Together, these cytokines activate cellular pathways that drive growth and division.

Getting the dosage just right is crucial. Research has pinpointed optimal cytokine concentrations for liquid suspension cultures. Too little results in poor cell yields, while too much can push stem cells to differentiate prematurely, reducing their potential for further expansion. Clinical trials using these optimized cytokine cocktails have shown impressive results, with a 330-fold expansion of CD34+ cells over 15 days. This highlights how effective these methods can be when carefully controlled, though maintaining stem cell quality by avoiding unwanted differentiation remains a key challenge.

Preventing Premature Cell Differentiation

While cytokines boost proliferation, small molecules are used to ensure stem cells stay undifferentiated. For example, StemRegenin-1 (SR-1) blocks the aryl hydrocarbon receptor, enabling a 50-fold expansion of CD34+ cells and a 17-fold increase in long-term repopulating cells. Similarly, Nicotinamide slows differentiation by inhibiting sirtuin enzymes, a mechanism central to the success of Omidubicel.

Another small molecule, UM171, works by inactivating the CoREST complex, suppressing genes responsible for differentiation. Research shows UM171 increases SCID-repopulating cells by 13-fold. Meanwhile, Tetraethylenepentamine (TEPA) takes a different route by chelating copper, as copper deficiency naturally slows the maturation of myeloid progenitors. Modern protocols often combine these small molecules with cytokines, effectively addressing the challenge of limited cord blood volume by achieving both higher cell counts and preserved stem cell quality.

Co-Culture with Mesenchymal Progenitor Cells

Recreating the bone marrow microenvironment offers another way to expand cord blood cells. Co-culturing them with Mesenchymal Stromal Cells (MSCs) mimics this natural environment. MSCs secrete supportive factors like SCF, Flt-3 ligand, and stromal cell-derived factor 1 (SDF-1) while also providing direct cell-to-cell contact. As EV Sotnezova from the Institute of Biomedical Problems of the Russian Academy of Sciences explains:

"Co-culturing with stromal feeder cells is a more physiological alternative to the application of recombinant cytokines."

A 2009 clinical trial at the University of Texas MD Anderson Cancer Center demonstrated the potential of this approach. Researchers used bone marrow-derived MSCs to expand cord blood cells over 14 days, achieving a 12-fold expansion of both total nucleated cells and CD34+ cells. Among six patients who received these expanded grafts, neutrophil engraftment occurred in a median of 14.5 days, and five remained in complete remission after one year. Studies show co-culture systems outperform liquid suspension methods in six out of eight performance measures, particularly in preserving primitive markers like CD34+ and CD90+.

Interestingly, the most primitive stem cells tend to migrate beneath the MSC layer, forming dense clusters known as "cobblestone areas." These areas provide a protective environment where the cells remain immature yet ready for transplantation. This spatial organization balances active cell growth with the preservation of undifferentiated cells, helping to overcome the limited volume of standard cord blood units.

Clinical Applications and Benefits for Families

Clinical Trial Results with Expanded Cells

Advances in cell expansion have delivered remarkable outcomes for patients, backed by compelling clinical trials. In December 2025, a study led by Dr. Richard Childs at the National Institutes of Health focused on 18 patients, aged 4 to 60, suffering from severe aplastic anemia. Using omidubicel (Omisirge), the trial achieved an impressive 94% survival rate without complications, with white blood cell recovery occurring in a median of eight days. This success played a key role in the FDA approving the treatment for refractory severe aplastic anemia.

Another significant study took place between 2013 and 2017, led by Dr. Mitchell Horwitz at the Duke Cancer Institute. This multicenter trial involved 36 adult patients with high-risk blood cancers, using NiCord, a nicotinamide-expanded cord blood unit. Results showed 94% of patients achieved successful engraftment within six weeks. Neutrophil recovery took just 11.5 days, while platelet recovery was reduced to 34 days. Patients also spent a median of 73 days out of the hospital in the first 100 days post-transplant - compared to 57 days with standard cord blood - marking a significant improvement in safety. Dr. Horwitz highlighted:

"Compared to standard cord blood transplant, the reduction in recovery time translates into significant improvement in the safety profile of the transplant procedure."

These findings demonstrate how expanded cells enhance safety, recovery, and overall outcomes, offering new hope for families seeking advanced medical solutions.

What Cell Expansion Means for Your Family

The success of cell expansion is reshaping the possibilities of cord blood banking for families. By addressing the natural volume limitations of cord blood, expansion technology ensures that a single stored unit can meet the therapeutic needs of an entire family.

For families banking with Americord, this means a single unit can now provide adequate cell counts for family members of all sizes, support repeated treatments, and even enable therapies for chronic conditions. Additionally, this technology allows for multiple treatments from one stored unit, which is especially important as regenerative medicine continues to grow. Dr. Colleen Delaney from the Fred Hutchinson Cancer Research Center explains:

"The real ground-breaking aspect of this research is that we have shown that you can manipulate stem/progenitor cells in the lab with the goal of increasing their numbers."

Expanded cells also exhibit enhanced properties for treating neurological conditions, showing higher levels of neurotrophic and angiogenic factors compared to unexpanded cells. With 36 clinical trials currently investigating expanded cord blood applications, the potential medical benefits of banking with Americord is worth it as these technologies continue to expand as these technologies move closer to widespread FDA approval.

Conclusion: Cord Blood Banking with Americord

Main Points to Remember

Ex vivo expansion is changing the game in cord blood banking. By multiplying stem cells outside the body before transplantation, this process enhances the effectiveness of treatments. The FDA approval of Omisirge highlights the clinical benefits of cell expansion, with studies showing quicker engraftment and lower infection risks. These advancements ensure that stored cord blood can meet the growing demands of modern therapies.

Scientific progress is also breaking previous limitations. Higher expansion rates mean cord blood can now be used for a broader range of patients, not just children or smaller adults. With cord blood currently treating over 80 diseases, its therapeutic possibilities continue to expand. These breakthroughs allow Americord to provide enhanced cord blood banking options.

Why Choose Americord

Americord stands out with its 5-compartment storage bag, allowing for up to five treatments from a single collection - far above the industry standard of two compartments. This flexibility is crucial as expansion techniques often require multiple treatment attempts.

Americord’s CryoMaxx™ Processing and advanced collection methods deliver impressive results: 60% more CD34+ stem cells, 54% higher cord blood volume, and 34% more total nucleated cells compared to industry averages. As Martin Smithmyer, CEO of Americord, puts it:

"From cutting-edge technology to industry-best processing standards, Americord employs every available tool to collect and preserve the largest volume of viable stem cells for our clients." – Martin Smithmyer, CEO, Americord

Additionally, Americord offers placental tissue banking, which significantly enhances expansion capabilities. Research indicates that mesenchymal stem cells from the placenta are far more effective at expanding hematopoietic stem cells than those from cord tissue and are on par with bone marrow MSCs - the current gold standard. With a $110,000 Cord Blood Quality Guarantee, storage at -196°F, and 24/7 monitoring, Americord combines cutting-edge science with reliability, giving families confidence in their choice as expansion technologies continue to evolve.

FAQs

Is expanded cord blood as safe as unexpanded cord blood?

Research indicates that expanded cord blood cells are safe, according to early clinical findings. Techniques for ex vivo expansion, which boost stem cell numbers, maintain safety while potentially enhancing engraftment. Emerging methods, like cytokine protocols, have shown encouraging safety results, suggesting that expanded cord blood cells could be used in a wider range of medical treatments with safety levels similar to unexpanded cells.

How long does cord blood expansion take before a transplant?

Cord blood expansion usually requires around 21 days before transplantation. Research involving ex vivo methods, like nicotinamide-based expansion, indicates an average timeline of about three weeks. This approach is designed to boost cell counts, making them suitable for a wider range of medical uses.

Can one stored cord blood unit be used more than once?

Yes, a stored cord blood unit can sometimes be used more than once thanks to ex vivo expansion. This technique boosts the number of stem cells in a single unit, allowing for multiple treatments or prolonging its usability. Such developments enhance the flexibility of cord blood in regenerative medicine and other medical treatments.